Lexeo Therapeutics Inc. (LXEO)
Lexeo Therapeutics Inc. (LXEO) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 426.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.27M |
| Beta | 1.47 |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.8 |
| P/B (ttm) | 1.66 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 4, 2026 |
| Ask | n/a |
| Volume | 22,776 |
| Avg. Volume (20D) | 939,262 |
| Open | 5.07 |
| Previous Close | 4.93 |
| Day's Range | 5.05 - 5.21 |
| 52-Week Range | 3.99 - 10.99 |
| Analyst | Strong Buy |
| Price Target | 20 (284.62%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac mu...
Financial Performance
In 2025, Lexeo Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -99.96M, an increase of 1.66%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for LXEO stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 284.62% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
